Clinical Trial
NCT06717438
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.